Covidien plc

Covidien — Merger or Acquisition (December 2011)

16 slides from Covidien's merger presentation, Dec 15, 2011

  1. Slide 1: Spin-off of Pharmaceuticals

  2. Slide 2: Forward-Looking Statements

    This presentation contains certain “forward-looking statements” that are not historical facts. These statements are based on management’s current expectations and are subject to risks, uncertainty and changes in circumstances, which may cause actual results to differ materially from anticipated resu

  3. Slide 3: Forward-Looking Statements (con't)

    – Other business effects, including the effects of industry, economic or political conditions outside of Covidien’s control – Transaction costs and other risks and uncertainties discussed in Covidien’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections of

  4. Slide 4: Non-GAAP financial measures notice

    This presentation discusses measures which may be considered “non-GAAP” financial measures under applicable Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in acco

  5. Slide 5: Definition of "New Covidien"

    References to “New Covidien” in this presentation reflect the Covidien plc historical reported GAAP results less the historical reported GAAP results of the Pharmaceuticals segment. These results are not necessarily representative of the results that will be reported by “New Covidien” or the Pharmac

  6. Slide 6: 2011 Net Sales

    Medical Supplies Medical Devices Pharma- ceuticals Active Pharmaceutical Ingredients Contrast Products Specialty Pharmaceuticals Radiopharmaceuticals Covidien $11.6B “New Covidien” $9.6B Pharmaceuticals $2.0B $598MM $494MM $416MM 2011 Net Sales 68% $7.8B 15% $1.8B 17% $2.0B 81% $7.8B 19% $1.8B $459M

  7. Slide 7: Product Portfolio – Covidien

    Endomechanical 20.2% Soft Tissue Repair 7.8% Energy 10.1% Oximetry & Monitoring 7.4% Airway & Ventilation 6.5% Vascular 12.3% Other Medical Devices 3.3% Specialty Pharmaceuticals 4.3% Active Pharmaceutical Ingredients 3.5% Contrast Products 5.2% Radiopharmaceuticals 4.0% Nursing Care 7.0% Medical Su

  8. Slide 8: Product Portfolio – "New Covidien"

    Endomechanical 24.4% Soft Tissue Repair 9.4% Energy 12.2% Oximetry & Monitoring 8.9% Airway & Ventilation 7.8% Vascular 14.8% Other Medical Devices 4.0% Nursing Care 8.4% Medical Surgical 4.6% SharpSafety 3.2% OEM 2.3% Medical Devices 81.5% Medical Supplies 18.5% * Based on 2011 sales Product Portfo

  9. Slide 9: 2011 Net Sales by Geography

    United States Europe* Other Americas Asia- Pacific Covidien $11.6 “New Covidien” $9.6 Pharmaceuticals $2.0 * Includes Europe, Middle East and Africa 2011 Net Sales by Geography ($ billions) 6% $0.7 55% $6.3 15% $1.8 24% $2.8 6% $0.6 53% $5.0 17% $1.6 24% $2.3 7% $0.2 66% $1.3 6% $0.1 21% $0.4

  10. Slide 10: Historical Sales Growth

    2011 2007-2011 Medical Devices Pharmaceuticals Medical Supplies Total Covidien “New Covidien” Pharmaceuticals * As reported 10.7% 0.0% 6.8% 8.5% 0.0% $7.8 2.0 1.8 $11.6 $9.6 2.0 CAGR Net Sales* 0.9% Historical Sales Growth ($ billions)

  11. Slide 11: 2011 Adjusted Gross Margin, R&D, Depreciation & Amortization

    Covidien* “New Covidien”* Pharmaceuticals Covidien “New Covidien” Pharmaceuticals $6,614 57.1% 60.0% $854 43.4% 4.8% $599 * Adjusted gross profit is a non-GAAP measure. See page 15 for reconciliation. Adjusted Gross Margin Gross Profit Adjusted Net Sales $5,760 $9,607 $1,967 $11,574 Depreciation & A

  12. Slide 12: 2011 Segment Operating Income

    Medical Devices $2,422 30.9% Pharmaceuticals 318 16.2% Medical Supplies Reportable Segments $2,987 25.8% Less Pharmaceuticals (318) “New Covidien” * Excludes Corporate and other unallocated expenses. 13.9% 247 Net Sales Operating Income 27.8% $2,669 % of 2011 Segment Operating Income* ($ millions)

  13. Slide 13: 2011 Segment Operating Income and Margin

    “New Covidien” Medical Devices $2,422 30.9% Pharma- ceuticals $318 16.2% Medical Supplies $247 13.9% 81.1% 10.6% 8.3% 90.7% 9.3% * Excludes Corporate and other unallocated expenses. Covidien 2011 Segment Operating Income and Margin* ($ millions)

  14. Slide 14: Manufacturing Footprint

    Covidien 48 Manufacturing facilities in 17 countries Pharmaceuticals 11 Manufacturing facilities in 5 countries “New Covidien” 37 Manufacturing facilities in 16 countries Manufacturing Footprint

  15. Slide 15: Reconciliations

    Covidien plc GAAP Gross profit Inventory charges Restructuring related charges, net Adjusted gross profit 4 56.8% 57.1% Gross margin $6,578 32 $6,614 percent 2011 Reconciliations ($ millions)

  16. Slide 16: December 15, 2011 – Spin-off of Pharmaceuticals

    December 15, 2011 Spin-off of Pharmaceuticals

Covidien — Merger or Acquisition (December 2011) on 6ix